|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shiraz University of Medical Sciences |
|---|---|
| Information provided by: | Shiraz University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00654290 |
Purpose
Atrial fibrillation is the most common arrhythmia post coronary bypass surgery, currently B-blockers are the class I indication to prevent AF post CABG. We decide to evaluate use of propranolol and amiodarone separately and together to find a better prophylaxis for AF peri-CABG
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation |
Drug: Amiodarone + Propranolol Drug: Amiodarone Drug: Propranolol |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft, A Prospective Double-Blind Randomized Study |
| Enrollment: | 240 |
| Study Start Date: | March 2007 |
| Study Completion Date: | February 2008 |
| Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
P: Experimental
Propranolol from 7 days pre-operation to 5 days post CABG
|
Drug: Propranolol
Propranolol from 7 days pre-operation to 5 days post CABG
|
|
A: Active Comparator
Amiodarone treated 7 days pre-operation to 5 days post CABG
|
Drug: Amiodarone
Amiodarone treated 7 days pre-operation to 5 days post CABG
|
|
AP: Active Comparator
Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
|
Drug: Amiodarone + Propranolol
Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
|
In this double blind randomized study 240 consecutive patients underwent elective coronary artery bypass grafting, being randomized prospectively into three groups, propranolol (p) (n=80), amiodarone (A) (n=80) and amiodarone with propranolol (AP) (n=80).
All groups received their medications from 7 days preoperatively and continued their medications for 5 days post CABG.
Eligibility| Ages Eligible for Study: | 45 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Iran, Islamic Republic of, Fars | |
| Shiraz University of Medical Sciences/Cardiac Surgery and Cardiology Ward/Namazi and Shahid Faghihi Hospital | |
| shiraz, Fars, Iran, Islamic Republic of, 71345 | |
More Information
| Responsible Party: | National Institute of Health ( shiraz university of medical sciences/Dr kojuri ) |
| Study ID Numbers: | 55318, NIH of IRAN |
| Study First Received: | April 2, 2008 |
| Last Updated: | April 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00654290 History of Changes |
| Health Authority: | Iran: National Institute of Health |
|
Atrial fibrillation coronary bypass Amiodarone Propranolol Coronary Artery Bypass Graft (CABG) |
|
Neurotransmitter Agents Vasodilator Agents Heart Diseases Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Amiodarone |
Pharmacologic Actions Pathologic Processes Propranolol Therapeutic Uses Adrenergic beta-Antagonists Adrenergic Antagonists Cardiovascular Diseases Atrial Fibrillation Anti-Arrhythmia Agents Arrhythmias, Cardiac |